Clinical Guide on Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis

on February 28, 2012 12:20 PM EST

Clinical guide on selective estrogen receptor modulators for postmenopausal osteoporosis
Postmenopausal osteoporosis and resulting fractures have a major impact on morbidity and mortality and are major public health issues. Various therapies such as bisphosphonates, strontium ranelate and more recently denomsumab are available but these are not suitable for all women. (Photo: flickr.com/fromcolettewithlove)

Publisher Elsevier announced today the publication of an important clinical guide from the European Menopause and Andropause Society (EMAS) in the February issue of Maturitas. This clinical guide details the role of selective estrogen receptor modulators (SERMs) against postmenopausal osteoporosis as the European Medicines Agency (EMA) has approved the use of bazedoxifene and lasofoxifene.

Postmenopausal osteoporosis and resulting fractures have a major impact on morbidity and mortality and are major public health issues. Various therapies such as bisphosphonates, strontium ranelate and more recently denomsumab are available but these are not suitable for all women. Health concerns have been raised resulting from these therapies, such as oesophageal cancer, osteonecrosis of the jaw (ONJ) and subtrochanteric fractures with bisphosphonates and venous thromboembolism with strontiumranelate. Use of bazedoxifene and lasofoxifene will increase the number of therapeutic options available as these new SERMs point to a greater anti-fracture potential.

Like Us on Facebook

The decision of which type of treatment to use for osteoporosis and when to begin should be based on the need to reduce fracture risk. All treatments including SERMs should include recommendations for a healthy life style and adequate calcium and vitamin D intake. Additional benefits of different agents (i.e. climacteric symptom improvement with estrogens, breast cancer prevention for SERMS) must be considered when selecting the anti-osteoporosis drug. Furthermore what agent is used (estrogen, SERM, bisphosphonates) may vary over a woman's life time. The clinical guide from the European Menopause and Andropause Society (EMAS) details all important and necessary aspects of consideration.

Source: Elsevier

© 2012 iScience Times All rights reserved. Do not reproduce without permission.

Join the Conversation

Sponsored From Around the Web

    ZergNet
Follow iScience Times
us on facebook RSS
 
us on google
 
Most Popular
INSIDE iScience Times
Do Dolphins Get High? BBC Cameras Catch Dolphins Chewing On Pufferfish Toxins
Do Dolphins Get High? BBC Cameras Catch Dolphins Chewing On Pufferfish Toxins
How Many Ways Can You Tie A Tie?
How Many Ways Can You Tie A Tie?
Ribbon Of Charged Particles At Solar System's Edge Acts Like A Wind Sock For Interstellar Magnetism
Ribbon Of Charged Particles At Solar System's Edge Acts Like A Wind Sock For Interstellar Magnetism
How to Turn Your Tap Water Faucet  Into a Coffee Spout [VIDEO]
How to Turn Your Tap Water Faucet Into a Coffee Spout [VIDEO]
Coolest Science Photos Of 2013: From Blobfish To Two-Headed Shark, Comet ISON To Mars Selfie
Coolest Science Photos Of 2013: From Blobfish To Two-Headed Shark, Comet ISON To Mars Selfie
This Is A Scientifically-Proven Rock-Paper-Scissors Winning Strategy (But If Your Opponent Uses It Too, It's A Draw)
This Is A Scientifically-Proven Rock-Paper-Scissors Winning Strategy (But If Your Opponent Uses It Too, It's A Draw)